Two 4N cell-cycle arrests contribute to cisplatin-resistance.
Cisplatin is a platinum-based drug that is used for the treatment of a wide-variety of primary human cancers. However, the therapeutic efficacy of cisplatin is often limited by intrinsic or acquired drug resistance. An important goal, therefore, is to identify mechanisms that lead to cisplatin resis...
Main Authors: | Hong Shen, Ricardo E Perez, Batzaya Davaadelger, Carl G Maki |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3613405?pdf=render |
Similar Items
-
Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.
by: Batzaya Davaadelger, et al.
Published: (2014-01-01) -
Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
by: Navin Sarin, et al.
Published: (2017-01-01) -
Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction
by: Fuguang Zhao, et al.
Published: (2020-12-01) -
<i>LNX1</i> Contributes to Cell Cycle Progression and Cisplatin Resistance
by: Minsu Jang, et al.
Published: (2021-08-01) -
Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells
by: Ying Xiong, et al.
Published: (2018-01-01)